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BACKGROUND: The impact of preexisting left bundle branch block 
(LBBB) in transcatheter aortic valve replacement (TAVR) recipients 
is unknown. The aim of this study was to determine the impact of 
preexisting LBBB on clinical outcomes after TAVR.
METHODS AND RESULTS: This multicenter study evaluated 3404 TAVR 
candidates according to the presence or absence of LBBB on baseline 
ECG. TAVR complications and causes of death were defined according to 
Valve Academic Research Consortium-2 definitions. Follow-up outpatient 
visits or telephone interviews were conducted at 30 days, 12 months, 
and yearly thereafter. Echocardiography examinations were performed 
at baseline, at hospital discharge, and at 1-year follow-up. Preexisting 
LBBB was present in 398 patients (11.7%) and was associated with an 
increased risk of permanent pacemaker implantation (PPI; 21.1% versus 
14.8%; adjusted odds ratio, 1.51; 95% CI, 1.12–2.04) but not death 
(7.3% versus 5.5%; adjusted odds ratio, 1.33; 95% CI, 0.84–2.12) at 30 
days. At a mean follow-up of 22±21 months, there were no differences 
between patients with and without preexisting LBBB in overall mortality 
(adjusted hazard ratio, 0.94; 95% CI, 0.75–1.18) and cardiovascular 
mortality (adjusted hazard ratio, 0.90; 95% CI, 0.68–1.21). In a 
subanalysis of 2421 patients without PPI at 30 days and with complete 
follow-up about the PPI, preexisting LBBB was not associated with an 
increased risk of PPI or sudden cardiac death. Patients with preexisting 
LBBB had a lower left ventricular ejection fraction (LVEF) at baseline and at 
1-year follow-up (P <0.001 for both), but those with low LVEF exhibited a 
similar increase in LVEF over time after TAVR compared with patients with 
no preexisting LBBB (P=0.327).
CONCLUSIONS: Preexisting LBBB significantly increased the risk of early 
(but not late) PPI after TAVR, without any significant effect on overall 
mortality or cardiovascular mortality. Preexisting LBBB was associated with 
lower LVEF pre-TAVR but did not prevent an increase in LVEF post-TAVR 
similar to patients without LBBB.
Quentin Fischer, MD et al
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The prevalence of left bundle branch block (LBBB) is <1% in the general population but increases in case of underlying cardiomyopa-
thy, as well as with age, from ≈0.5% at 50 years to 
5% at 80 years.1 LBBB has been associated with an 
increased risk of adverse outcomes, including major 
cardiac events and mortality.2–4 Indeed, LBBB results 
in persistent asynchronous ventricular activation,5 
which may lead to a redistribution of myocardial 
blood flow with septal hypoperfusion, left ventricular 
(LV) remodeling with ventricular dilatation, asymmet-
rical hypertrophy, mitral regurgitation, and reduction 
of LV ejection fraction (LVEF).6–8 This may become a 
vicious cycle with progressive LV failure, which often 
correlates with further progression of the conduction 
abnormality as well.
Transcatheter aortic valve replacement (TAVR) is a 
well-established therapy for patients with aortic ste-
nosis and intermediate-to-prohibitive surgical risk.9 
However, the occurrence of conduction disturbances 
and the need for permanent pacemaker implanta-
tion (PPI) remain the most frequent complications of 
TAVR.10 Preexisting right bundle branch block (RBBB) 
has been identified as the most important risk factor 
for PPI post-TAVR,10 and some studies have shown 
an increased mortality risk among patients with pre-
existing RBBB.11,12 However, no specific data exist on 
the impact of preexisting LBBB on TAVR outcomes. 
Therefore, the aim of this study was to evaluate the 
impact of preexisting LBBB on clinical outcomes in 
patients undergoing TAVR.
METHODS
Population
The data, analytic methods, and study materials will be avail-
able to other researchers for purposes of reproducing the 
results (the author for correspondence should be contacted 
for the data). A total of 4513 patients underwent TAVR in 
18 centers between February 2005 and October 2017. Of 
these, 4434 patients with high-quality ECGs at baseline 
were included in the present analysis and grouped accord-
ing to the presence of baseline complete LBBB. Patients with 
complete RBBB (n=434) or previous pacemaker (n=596) were 
excluded from the study, leading to a final study popula-
tion of 3404 patients. Patients with incomplete LBBB were 
considered as no preexisting LBBB. TAVR indication, valve 
type, and approach were determined by each center’s heart 
team. Clinical outcomes were defined according to the Valve 
Academic Research Consortium-2 definitions.13
Twelve-lead electrocardiographic tracings were recorded at 
baseline and at hospital discharge. Intraventricular conduction 
abnormalities were classified according to the American Heart 
Association, American College of Cardiology Foundation, and 
Heart Rhythm Society recommendations for standardization 
and interpretation of the ECG.14 PPI was mainly performed 
if third-degree or advanced second-degree atrioventricular 
block occurred at any anatomic level and was not expected 
to resolve or in the presence of sinus node dysfunction and 
documented symptomatic bradycardia, in agreement with 
current recommendations.15 However, the final indication for 
PPI was at the discretion of the physician responsible for the 
patient, with no prospective or centralized control about the 
decision and reasons for PPI. Therefore, the possibility of PPI 
out of current guideline recommendations in some cases can-
not be excluded. Data were collected in accordance to the 
ethics committee of each participating center, and all patients 
provided signed informed consent for the procedures.
Follow-Up
Follow-up was undertaken by telephone and on-site clini-
cal visit at 1 month, 1 year, and yearly thereafter. Follow-up 
was obtained in 97.2% of patients (94 patients, 2.8% of the 
study population, were lost to follow-up), and the mean fol-
low-up was 22±21 months. Complete follow-up about the 
time for PPI was obtained in a subgroup of 2564 patients 
(75.3%). Rate of complete follow-up was similar in both 
groups (77.1% in the LBBB group versus 75.1% in the no-
LBBB group; P=0.372).
Complete echocardiography examinations were obtained 
at baseline (3349 patients; 98.4% of the population), at hos-
pital discharge/1-month follow-up (2819 patients; 88.6% of 
patients alive at hospital discharge), and at 1-year follow-up 
(1689 patients; 58.0% of the patients at risk at 1-year follow-
up). Changes in LVEF were analyzed in all patients with com-
plete echocardiography at  the 3 time points.
Outcomes
The primary outcomes of this analysis were (1) PPI and (2) 
cumulative all-cause mortality. Secondary outcomes were car-
diovascular death, sudden cardiac death (SCD), and changes in 
LVEF over time. All outcomes were evaluated according to the 
WHAT IS KNOWN
• Preexisting right bundle branch block has been 
identified as the most important risk factor for 
permanent pacemaker implantation post-trans-
catheter aortic valve replacement, and some 
studies have shown an increased mortality risk 
among patients with preexisting right bundle 
branch block. However, no specific data exist 
on the impact of preexisting left bundle branch 
block on transcatheter aortic valve replacement 
outcomes.
WHAT THE STUDY ADDS
• In transcatheter aortic valve replacement recipi-
ents, preexisting left bundle branch block increases 
the risk of permanent pacemaker implantation but 
not mortality at 30 days.
• Preexisting left bundle branch block does not 
associate with increased mortality or heart fail-
ure hospitalization at 2-year follow-up, and most 
patients improve their left ventricular ejection 
fraction over time.
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presence of baseline LBBB. Morphology of the QRS on base-
line ECG was available in all patients. Methods used to assess 
causes of death were published previously.16 Cardiovascular 
death was defined according to Valve Academic Research 
Consortium-2 criteria. SCD was defined, in accordance with 
the World Health Organization definition, as a death occur-
ring within 1 hour of symptom onset if witnessed or within 
the previous 24 hours if unwitnessed. Patients with known 
terminal disease or an identifiable noncardiac cause of sud-
den death were not considered to have experienced SCD.17
Statistical Analysis
Qualitative variables were expressed as number (percent-
age), whereas continuous data were presented as mean±SD 
or median (interquartile range) depending on their distribu-
tion. Survival rates were summarized using Kaplan-Meier 
estimates including all events ≤24-month follow-up, and 
log-rank tests were used to compare groups. Differences 
between groups in clinical outcomes were analyzed using a 
logistic regression (30-day outcomes) or Cox proportional-
hazards models to adjust for baseline differences between 
groups. The variables included in the model were age, sex, 
atrial fibrillation, chronic kidney disease, LVEF <50%, and 
mean gradient. An ANOVA for repeated measures model 
with interaction was used to analyze the changes in LVEF 
over time. Posterior comparisons were performed using the 
Tukey post hoc test. All tests were 2 sided at the 0.05 sig-
nificance level. Statistical analyses were conducted with the 
statistical package SAS, version 9.3 (SAS Institute, Cary, NC).
RESULTS
The main clinical characteristics, echocardiographic, 
and procedural findings of the study population are 
shown in Table 1. Patients in the LBBB group were older, 
had a higher operative risk, and a lower baseline LVEF 
(P <0.03 for all). There were no differences between 
groups about the procedural findings, approach, and 
transcatheter valve type.
The 30-day outcomes according to preexisting 
LBBB are shown in Table 2. At 30 days, the mortality 
rate was similar in the preexisting LBBB and no-LBBB 
groups (7.3% versus 5.5%; adjusted odds ratio, 1.33; 
95% CI, 0.84–2.12; P=0.217). PPI occurred in 21.1% 
of patients with preexisting LBBB compared with 14.8% 
in the no-LBBB group (adjusted odds ratio, 1.51; 95% 
CI, 1.12–2.04; P=0.006). At 30 days, no patient had 
a cardiac resynchronization therapy, and pacemaker 
type (single versus dual chamber) was similar in both 
groups (adjusted odds ratio, 1.08; 95% CI, 0.43–2.73; 
P=0.864). The PPI rate was higher in those patients 
receiving a self-expandable valve (23.1% versus 8.7% 
for balloon-expandable valves; P<0.001), as well as dur-
ing the second (2012–2017) versus first (2005–2011) 
study time periods (16.9% versus 13.9%; P=0.015). The 
rate of LBBB pre-TAVR was similar in the first and second 
study time periods (11.5% versus 12.0%; P=0.630).
In the no-LBBB group, a total of 2463 (72.4%) 
patients had a completely normal ventricular conduc-
tion, whereas 278 (9.2%), 10 (0.3%), 66 (2.2%), and 
189 (6.3%) patients had a left anterior hemiblock, a 
left posterior hemiblock, an incomplete LBBB, and a 
nonspecific intraventricular conduction delay, respec-
tively. The 30-day PPI rate was 14.3% in those patients 
with normal ventricular conduction versus 16.9% in 
Table 1. Baseline and Procedural Findings of the Study Population, 
According to Preexisting LBBB
Variables LBBB (n=398)
No LBBB 
(n=3006) P Value
Baseline clinical characteristics
  Age, y 82.0±7.1 81.0±8.1 0.014
  Men 218 (54.8) 1392 (46.3) 0.002
  Body mass index, kg/m2 26.5±5.0 26.7±5.1 0.452
  Hypertension 302 (75.9) 2237 (75.1) 0.725
  Diabetes mellitus 104 (26.1) 878 (29.4) 0.172
  Atrial fibrillation 133 (33.9) 814 (27.8) 0.01
  Previous cardiac surgery 97 (25.8) 624 (23.0) 0.226
  Coronary artery disease 203 (51.0) 1438 (48.1) 0.275
  Complete or no need for 
revascularization
278 (74.3) 2117 (75.3) 0.697
  Chronic obstructive 
pulmonary disease
92 (23.1) 679 (22.8) 0.875
  Chronic kidney disease (eGFR, 
<60 mL/min)
213 (56.2) 1444 (50.1) 0.026
  Peripheral artery disease 75 (19.6) 529 (19.0) 0.794
  STS score, % 6.2±4.0 5.5±3.2 0.024
Echocardiographic findings
  Left ventricular ejection 
fraction, %
48.8±16.3 56.9±12.9 <0.001
  Left ventricular ejection 
fraction ≤50%
186 (48.4) 757 (25.8) <0.001
  Mean transaortic gradient, 
mm Hg
44.0±16.2 48.6±16.8 <0.001
  sPAP>60 mm Hg 42 (14.9) 240 (11.8) 0.130
Procedural findings
  Primary access   0.626
   Transfemoral 319 (80.2) 2444 (81.3)
   Subclavian 13 (3.3) 62 (2.1)
   Transapical 54 (13.6) 424 (14.1)
   Transaortic 7 (1.8) 40 (1.3)
  Valve type   0.355
   Self-expandable 191 (48.1) 1369 (45.6)
   Balloon expandable 206 (51.9) 1630 (54.4)
  Implantation success (VARC-2) 336 (85.9) 2471 (83.4) 0.206
  Median length of stay, d (IQR) 7 (5–13.5) 7 (5–12) 0.347
eGFR indicates estimated glomerular filtration rate; IQR, interquartile range; 
LBBB, left bundle branch block; sPAP, systolic pulmonary artery pressure; 
STS, Society of Thoracic Surgeons; and VARC-2, Valve Academic Research 
Consortium-2.
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patients with left anterior hemiblock (P=0.249), 20.0% 
in patients with a left posterior hemiblock (P=0.610), 
16.7% in patients with an incomplete LBBB (P=0.594), 
and 14.4% in patients with a nonspecific intraventricu-
lar conduction delay (P=0.991).
Late Clinical Outcomes
At a mean follow-up of 22±21 months, 914 patients 
(26.9%) had died. Cardiovascular death occurred in 573 
patients (16.8%), including heart failure (HF) death in 
154 patients (4.5%) and SCD in 84 patients (2.5%). Late 
clinical events post-TAVR grouped according to preexist-
ing LBBB are shown in Table 3. There were no differences 
between groups in late all-cause mortality (adjusted haz-
ard ratio, 0.84; 95% CI, 0.64–1.08; P=0.173) or cardio-
vascular mortality (adjusted hazard ratio, 0.74; 95% CI, 
0.51–1.05; P=0.093). The Kaplan-Meier curves for clinical 
events (mortality, cardiovascular mortality, and hospital-
ization for HF) ≤2-year follow-up are shown in Figure 1.
The cumulative rate of PPI was higher in the preexist-
ing LBBB group (22.9% versus 16.5%; hazard ratio, 1.40; 
95% CI, 1.11–1.78; P=0.006). However, this was because 
of an increased PPI rate early after TAVR (median time of 
PPI, 4 [interquartile range, 1–7] days), and no differences 
between groups were observed in the PPI rate after the 
first 30 days post-TAVR (preexisting LBBB, 2.2%; no pre-
existing LBBB, 1.9%; adjusted hazard ratio, 0.95; 95% CI, 
0.45–2.03; P=0.904). The Kaplan-Meier curves for PPI and 
SCD are shown in Figure 2. There were no differences in 
late (>30 days) sudden death or PPI between groups.
LVEF Changes After TAVR
Patients in the preexisting LBBB group had a baseline 
LVEF significantly lower than patients with no preexisting 
Table 2. Thirty-Day Outcomes, According to the Presence of Preexisting LBBB
Variables
LBBB 
(n=398)
No LBBB 
(n=3006) OR (95% CI) P Value
Adjusted OR (95% 
CI) P Value
Death 29 (7.3) 165 (5.5) 1.43 (0.95–2.17) 0.089 1.33 (0.84–2.12) 0.217
Cardiovascular death 25 (6.3) 141 (4.7) 1.44 (0.93–2.25) 0.106 1.39 (0.85–2.27) 0.189
Stroke 16 (4.0) 105 (3.5) 1.15 (0.67–1.97) 0.619 0.85 (0.45–1.62) 0.633
Myocardial infarction 7 (1.8) 36 (1.2) 1.61 (0.70–3.68) 0.263 1.27 (0.50–3.19) 0.618
Major or life-threatening 
bleeding event
60 (15.1) 413 (13.8) 1.26 (0.93–1.70) 0.135 1.35 (0.98–1.86) 0.067
New pacemaker 84 (21.1) 445 (14.8) 1.37 (1.04–1.81) 0.023 1.51 (1.12–2.04) 0.006
Moderate or severe aortic 
regurgitation
37 (10.8) 282 (10.8) 0.92 (0.63–1.34) 0.668 0.81 (0.53–1.23) 0.322
LBBB indicates left bundle branch block; and OR, odds ratio.
Table 3. Late Outcomes After TAVR, According to the Presence of Preexisting LBBB
Variables
LBBB 
(n=398)
No LBBB 
(n=3006) HR (95% CI) P Value
Adjusted HR (95% 
CI) P Value
Late outcomes (>30 d)*
  Death 79 (21.4) 641 (22.6) 0.91 (0.71–1.16) 0.431 0.84 (0.64–1.08) 0.173
  Cardiovascular death 43 (11.5) 364 (12.7) 0.86 (0.62–1.20) 0.384 0.74 (0.51–1.05) 0.093
  Stroke 6 (1.6) 44 (1.5) 1.09 (0.43–2.77) 0.863 1.15 (0.41–3.24) 0.789
  Myocardial infarction 0 12 (0.4) … … … …
  New pacemaker 7 (2.2) 50 (1.9) 1.22 (0.53–2.79) 0.642 0.95 (0.45–2.03) 0.904
  Hospitalization for HF 39 (10.1) 239 (8.2) 1.20 (0.84–1.70) 0.319 1.07 (0.74–1.55) 0.706
Cumulative outcomes†
  Death 108 (27.1) 806 (26.8) 1.01 (0.81–1.24) 0.978 0.94 (0.75–1.18) 0.596
  Cardiovascular death 68 (17.1) 505 (16.8) 1.01 (0.78–1.32) 0.938 0.90 (0.68–1.21) 0.509
  Stroke 22 (5.5) 149 (4.9) 1.16 (0.73–1.82) 0.533 1.09 (0.68–1.76) 0.735
  Myocardial infarction 7 (1.8) 48 (1.6) 1.20 (0.55–2.62) 0.650 1.16 (0.52–2.64) 0.713
  New pacemaker 91 (22.9) 495 (16.5) 1.41 (1.12–1.78) 0.004 1.40 (1.11–1.78) 0.006
  Hospitalization for HF 52 (13.1) 320 (10.7) 1.20 (0.89–1.62) 0.243 1.05 (0.76–1.44) 0.785
LBBB indicates left bundle branch block; HF, heart failure; HR, hazard ratio; and TAVR, transcatheter aortic valve replacement.
*Late outcomes were defined by outcomes occurring after the first 30 d post-TAVR. Patients whose events occurred before 30 d 
were excluded of this analysis.
†Cumulative outcomes were showed without time censure.
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LBBB (48.4±0.8% versus 57.0±0.2%; P<0.001). At dis-
charge, LVEF increased in both groups (51.3±0.8% in the 
preexisting LBBB group, Δ+2.9±0.7% versus 58.4±0.2% 
in the no preexisting LBBB group, Δ+1.4±0.2%). LVEF 
continued to increase in both groups during follow-up 
(at 12-month follow-up: 52.6±0.9% in the preexisting 
LBBB group, Δ+4.2±0.9% versus 59.1±0.3% in the no 
preexisting LBBB, Δ+2.0±0.3%). Despite a lower LVEF 
in the preexisting LBBB group, the relative increase of 
the LVEF 1 year post-TAVR was not significantly different 
between the 2 groups (P=0.085; Figure 3A). Likewise, 
among patients with baseline LVEF ≤50%, LVEF increased 
from 38.8±0.4% at baseline to 46.2±0.6% at hospital 
discharge (Δ+7.4±0.4%) and reached 50.2±0.6% 1 
year after TAVR (Δ+11.4±0.6%). LVEF increased in both 
groups at discharge (42.0±1.1% in the preexisting LBBB 
group, Δ+7.3±0.9% versus 47.4±0.6% in the no pre-
existing LBBB group, Δ+7.4±0.5%) and continued to 
increase in both groups during follow-up (45.6±1.3% 
in the preexisting LBBB group, Δ+10.9±1.3% versus 
51.6±0.6% in the no preexisting LBBB group at 1 year, 
Δ+11.5±0.6%; Figure 3B). Among patients with base-
line LVEF <50%, similar changes in LVEF over time were 
observed in the preexisting LBBB and no preexisting 
LBBB groups (P=0.327).
DISCUSSION
In patients undergoing TAVR, preexisting LBBB was 
associated with an increased risk of PPI but not mor-
tality at 30 days. Preexisting LBBB had no deleterious 
effect on late outcomes, including overall and cardio-
vascular mortality. Patients with preexisting LBBB exhib-
ited a lower LVEF pre-TAVR but experienced a similar 
degree of increase in LVEF at 1-year follow-up com-
pared with those patients with no significant conduc-
tion disturbances pre-TAVR.
Previous studies have shown a prevalence of LBBB 
in TAVR candidates close to 10%,12,16,18 and the slightly 
higher rate observed in our study (≈12%) may be 
related to the exclusion of patients with other conduc-
tion abnormalities, such as RBBB or those with prior 
Figure 1. Clinical events at 2-y follow-up, according to preexisting left bundle branch block (LBBB).  
A, Kaplan-Meier curves at 2-y follow-up for overall mortality according to the presence of preexisting LBBB. B, Kaplan-Meier curves at 2-y follow-up for cardiovas-
cular mortality according to the presence of preexisting LBBB. C, Kaplan-Meier curves at 2-y follow-up for hospitalization for heart failure according to the pres-
ence of preexisting LBBB. D, Kaplan-Meier curves at 2-y follow-up for overall mortality or hospitalization for heart failure according to the presence of preexisting 
LBBB. HR indicates hazard ratio.
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pacemaker. The development of ventricular conduc-
tion disorders, particularly LBBB, can result from either 
intrinsic conduction system degeneration or an extrin-
sic insult from a variety of cardiovascular diseases.19 
Several factors have been associated with LBBB devel-
opment, including LV hypertrophy, increased cardiac 
volume, hypertension, valvular heart disease, car-
diomyopathies, myocarditis, and coronary artery dis-
ease.20,21 Most patients with severe aortic stenosis have 
many of these risk factors, and this may explain the 
higher rate of LBBB in this population compared with 
the general population.
The rates of PPI after TAVR are highly variable but 
average 13%,10 and no significant decrease in the 
incidence of PPI has been observed in the past years, 
despite the increasing experience of centers/operators 
and the use of newer generation valve systems.10,22 
Multiple risk factors have been identified as indepen-
dent predictors for PPI post-TAVR, like valve type, LV 
outflow tract calcium load, implantation depth, or pre-
existing RBBB.10,23 The His bundle bifurcates into the 
right and left bundles at the inferior border of the mem-
branous septum, with the latter emerging beneath the 
noncoronary cusp. Therefore, valve implantation that 
overlaps the distal membranous septum may affect both 
the right and left bundles and lead to complete heart 
block. Electrophysiological studies showed that aor-
tic valve implantation increases the risk of conduction 
disturbances, most likely by increasing the His-ventricle 
interval or inducing an infra-Hisian block.24 Our study 
was the first to highlight that baseline LBBB significantly 
increases the risk of PPI after TAVR. Importantly, the 
increased risk occurred early after TAVR, probably sec-
ondary to the mechanical compression of the His bundle 
during valve implantation, and no significant increase in 
the rate of late PPI or SCD was observed at 2-year fol-
low-up. This provides some reassurance about the man-
agement of these patients in the absence of advanced 
conduction disturbances during the hospitalization 
period and contrasts with the results observed in the 
presence of new-onset LBBB post-TAVR, which seems 
to determine an increased risk of PPI and SCD within 
Figure 2. Permanent pacemaker implantation and sudden cardiac death at 2-y follow-up, according to preexisting left bundle branch block (LBBB).  
A, Kaplan-Meier curves at 2-y follow-up for permanent pacemaker implantation (PPI) according to the presence of preexisting LBBB. B, Kaplan-Meier curves for 
PPI between 30 d and 2 y according to the presence of preexisting LBBB in patients with no PPI at 30-d follow-up. C, Kaplan-Meier curves for sudden cardiac 
death (SCD) between 30 d and 2 y according to the presence of preexisting LBBB in patients with no PPI at 30-d follow-up. D, Kaplan-Meier curves for SCD or PPI 
between 30 d and 2 y according to the presence of preexisting LBBB in patients with no PPI at 30-d follow-up. HR indicates hazard ratio.
D
ow
nloaded from
 http://ahajournals.org by on February 21, 2019
Fischer et al; LBBB in TAVR Recipients
Circ Cardiovasc Interv. 2018;11:e006927. DOI: 10.1161/CIRCINTERVENTIONS.118.006927 October 2018 7
the months after the procedure.10,16,25 Interestingly, the 
presence of preexisting LBBB has already been identified 
as an important risk factor for PPI after surgical aortic 
valve replacement.26 These results should be taken into 
account in the preparation of the TAVR procedures, con-
sidering the use of a valve type associated with a lower 
risk of conduction disturbance issues and a high (more 
aortic) transcatheter valve positioning in those patients 
with preexisting LBBB, to decrease the PPI after TAVR.
Several studies in nonaortic stenosis populations 
have shown the negative effects of LBBB on long-term 
(≥10 years) outcomes, particularly in elderly patients 
and in the presence of underlying heart disease.27–33 The 
lack of increase in mortality risk at 2-year follow-up in 
our study may be because of the positive effects related 
to the treatment of aortic stenosis and the increase in 
the LVEF post-TAVR along with the shorter follow-up 
compared with prior studies in the general population 
and in patients with other cardiomyopathies. A con-
tinuous follow-up of such patients will be important in 
determining the impact of preexisting LBBB on longer 
term clinical outcomes post-TAVR.
In patients with HF and reduced LVEF, LBBB is associ-
ated with an increased incidence of sudden death, all-
cause mortality, and acute HF.34–36 In contrast, we failed 
to find an increase in the rate of hospitalizations for HF 
among TAVR recipients with preexisting LBBB, despite a 
lower LVEF in this group. This could be partially explained 
by a similar improvement in LV function in patients with 
and without preexisting LBBB within the months after 
TAVR. Unlike other studies in patients with other cardiac 
diseases, even those patients with LBBB and reduced 
LVEF at inclusion experienced similar improvement in 
LVEF than patients without LBBB during follow-up. A 
recent study found that patients with LBBB and mild-to-
moderate LV dysfunction (LVEF between 36% and 50%) 
have exceedingly poor outcomes. At 5 years, 59% of 
patients had died, further decreased their LVEF ≤35%, 
had a sustained ventricular arrhythmia, or required 
device implantation.37 LBBB results in dysynchronous 
electrical activation of the ventricles and inefficient con-
traction of the LV and may lead to progressive LV failure. 
This process may be disrupted by cardiac resynchroniza-
tion therapy, and the indication for resynchronization 
should be evaluated in patients with complete LBBB and 
persistent LVEF ≤35% after TAVR. However, the results 
of the present study showing significant improvements 
in LVEF in a high proportion of patients strongly suggest 
that this evaluation should not be performed immedi-
ately but several months after the TAVR procedure.
Study Limitations
Given the nonrandomized nature of the study, the pres-
ence of unmeasured confounders that may influence 
the relationship between LBBB and outcomes cannot 
be excluded.
Although the causes of death at each center were 
defined according to the Valve Academic Research 
Consortium-2 criteria, no event adjudication commit-
tee was available in this study. Electrocardiographic and 
echocardiographic findings were interpreted at each 
center, with no electrocardiographic or echocardio-
graphic core laboratory evaluation. Depth of implant, 
degree of LV outflow tract calcification, and duration 
of the PR interval on baseline ECG were not available 
in most patients, precluding an analysis of the impact 
of these factors in PPI rates. In addition, echocardio-
graphic data at 1-year follow-up were available in 
≈60% of patients. Data about the use of atrioventricu-
lar node–blocking medications, which may affect the 
PPI, were not available. Finally, the indication for PPI 
during follow-up was not collected in all centers.
Figure 3. Changes in left ventricular ejection fraction (LVEF) after trans-
catheter aortic valve replacement (TAVR), according to preexisting left 
bundle branch block (LBBB).  
A, LVEF changes over time in overall population. B, LVEF changes over time 
after TAVR in patients with LVEF <50% at baseline.
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Conclusions
The results of this study show that preexisting LBBB 
increased the risk for PPI early post-TAVR. However, 
preexisting LBBB in TAVR recipients was not associated 
with increased mortality or HF hospitalization at 2-year 
follow-up, and there were significant improvements in 
LVEF in most patients. This suggests that the possible 
use of specific therapies, including cardiac resynchro-
nization therapy, should be delayed by several months 
to avoid implementing unnecessary treatment. Future 
studies should determine the longer term outcomes of 
such patients.
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